PARADIGM study (PAnitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC)

ABSTRACT: Interventions: Randomization Primary outcome(s): The following item concerning all sites and a primary tumor occupying a left-sided site* (hereinafter referred to as left-side) Overall survival (OS) *:Primary tumors occupying a left-sided site include the descending colon, sigmoid colon, and rectum. Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2614086 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR